Step 5: Effective Drug Treatment of HIV
See also Antiretroviral Therapy, Adherence, and Initiating Treatment
Active Resources: 71
Webinars
-
12/7/2016
-
11/14/2016
-
10/26/2015
-
2/19/2015
-
3/28/2014
-
2/19/2013
Toolkits
-
11/23/2016
-
5/17/2016
-
4/29/2015
-
7/31/2014
Pocket Guides
-
11/22/2016
-
9/7/2015
-
4/1/2015 (reviewed: 11/22/2016)
-
3/1/2015 (reviewed: 11/22/2016)
-
2/13/2015 (reviewed: 10/31/2014)
-
8/15/2014
-
2/1/2014
-
11/30/2013
-
11/1/2013
-
7/1/2013
-
4/1/2013
Online Training
-
9/22/2016
-
1/1/2014
Videos
-
8/25/2016
-
7/17/2014
-
9/2/2013
Slide Sets
-
7/28/2016
-
8/25/2015
-
8/11/2015
-
6/11/2015
-
5/19/2015
-
5/19/2015
-
12/22/2014 (reviewed: 7/17/2015)
-
1/15/2014
Image Library
-
4/6/2016
Fact Sheets
-
2/12/2016
Reports
-
2/1/2016
-
2/6/2015
Charts, Tables & Posters
-
11/11/2015
-
9/4/2015
-
7/1/2015
-
4/1/2015
-
2/23/2015
-
10/24/2014
-
8/22/2014
-
7/9/2014
-
6/1/2013 (reviewed: 1/11/2017)
-
3/1/2013
-
2/1/2013
-
1/1/2013
Primary Care Guidelines
-
11/9/2015
-
11/13/2013
Articles & Bibliographies
-
10/5/2015
-
4/21/2014
-
4/21/2014
-
3/6/2014
-
2/14/2014
-
11/1/2012
Clinical Reference Tools
-
9/10/2015
Antiretroviral Guidelines
-
8/6/2015 (reviewed: 10/26/2016)
-
3/3/2015 (reviewed: 4/27/2017)
-
5/1/2014 (reviewed: 7/14/2016)
Patient Information
-
7/7/2014
-
9/29/2013
-
2/1/2013
-
1/1/2013
-
1/1/2013
Manuals
-
4/30/2014
-
11/1/2013
-
3/1/2013
Coinfection Guidelines (Hep, TB, STIs)
-
3/27/2014 (reviewed: 10/31/2016)
Archive Resources: 8
Slide Sets
-
4/11/2014
-
12/1/2011
-
7/8/2011
Curricula
-
11/1/2012
OIs & Complications Guidelines
-
1/1/2012
Charts, Tables & Posters
-
7/1/2011
Fact Sheets
Self-Study Materials
-
1/1/2010
Articles: 9
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics
The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.
It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression
The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...
-
Pyrimethamine Availability
Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...
-
Adult and Adolescent Guidelines: Major Changes
The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.
Efavirenz/TDF/FTC (Atripla) has... -
Two New Boosted-PI Coformulations
Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:
Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...
-
Efavirenz Updates: Bone Mineral Density & Suicidality
Efavirenz and Bone Mineral DensityPersons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (...
| Day | Title |
|---|---|
|
6/4 |
|
|
6/5 |
HIV Long-Term Survivors Day
Event type: Awareness Days
|
|
10/23 |
| Day | Title |
|---|---|
|
5/22 |
|
|
3/24 |
|
|
3/7 |
|
|
2/13 |
CROI 2017: Seattle
Event type: Conferences & Events
|